Evolocumab vs Inclisiran

Hi everyone, I’m an OBGYN SR 🙋‍♀️ seeking some practical guidance regarding Repatha (evolocumab) access in India for my father. He is a 64-year-old male who recently underwent left main coronary stenting and is currently on maximally tolerated medical therapy (rosuvastatin + ezetimibe + DAPT etc).

I've been diagnosed with 2 soft plaques (one in my heart at 35% stenosis and one in my right carotid at 45% stenosis) back in early July. Calcium score is 0. My cardiologist immediately put me on Rosuvastatin+Ezetimibe 20+10, Colchicine 1mg and Aspirin 100mg; I was taking them religiously for 8 week

About 8 weeks ago I (M, 50), started with 5mg Rosuvastatin due to an LDL cholesterol level of >160 and a scan of my neck vessels showing first signs of atherosclerosis. Before, I tried different diet changes, with no results larger than a 10% drop. After 4 weeks of just 5mg Rosuva my LDL came

Hi everyone, I’m an OBGYN SR 🙋‍♀️ seeking some practical guidance regarding Repatha (evolocumab) access in India for my father. He is a 64-year-old male who recently underwent left main coronary stenting and is currently on maximally tolerated medical therapy (rosuvastatin + ezetimibe + DAPT etc).

Hi all, Posting on behalf of my mom (F55). She has familial cholesterol and is unable to take statin meds (due to adverse reaction that effects her muscles) so she was put on rapatha injections that are done every 2 weeks. This is the only option we had in Canada and she was having significant side

​ Some of you may remember me from [This Post](https://www.reddit.com/r/wallstreetbets/comments/dv83sb/arwr_will_be_the_next_top_pharmaceutical_company/?utm_source=share&utm_medium=web2x) where I talked about ARWR when it was sitting around $40 before it broke out and hit an ATH of $7

**47M with CAC 743** – Looking for Perspective I’m a 47-year-old male who recently had a coronary artery calcium (CAC) score of 743.9 (Agatston), which puts me >90th percentile for my age/sex. # CAC Breakdown: * Left Main: 146.0 * LAD: 171.5 * LCx: 237.1 * RCA: 189.4 * PDA: 0 Report impression:

**ALNY** ALNY is our top pick for 2022 as it nears a key inflection point: APOLLO-B data of patisiran in TTR-CM (mid- 22). This is set up for success given precedent cardiac subset data from TTR-PN trials. We model $2B+ sales for patisiran/vutrisiran in TTR-CM achievable given current $2B sales of

I have a stent and my numbers are not ideal LDL hovers between 90-110. However, HDL is 70 and Tryglicerides are very good (38 last time I checked). I take Crestor 20 mg. With life style and diet this is the best I can get. The doctor pushes me to do something to get LDL under 70. Here's where I stan

This is an automatic summary, [original](http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_17-3-2017-14-40-10) reduced by 78%. ***** > The first in a new class of gene-silencing drugs, known as inclisiran, has halved cholesterol levels in patients at risk of cardiovas